The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size. (February 2015)

• Record Type: Journal Article
• Authors: Govoni, Mirco; Piccinno, Annalisa; Lucci, Germano; Poli, Gianluigi; Acerbi, Daniela; Baronio, Roberta; Singh, Dave; Kuna, Piotr; Chawes, Bo L.K.; Bisgaard, Hans
• Is Part Of: Pulmonary pharmacology & therapeutics. Volume 30(2015:Feb.)
• Page Start: 102
• Page End: 109
• Publication Date: 2015-02
• Subjects: Beclometasone -- Formoterol -- Children -- Adolescents -- Adults -- Asthma; AUC area under the plasma drug concentration-time curve -- BDP beclometasone-dipropionate -- B17MP beclometasone-17-monopropionate -- Cmax maximum plasma concentration -- FEV1 forced expiratory volume in 1 s -- FF formoterol-fumarate -- ICS inhaled corticosteroids -- PK pharmacokinetics -- pMDI pressurized metered dose inhaler -- t1/2 half-life -- tmax time to maximum plasma concentration -- VHC valved holding chamber; Respiratory organs -- Diseases -- Chemotherapy -- Periodicals; 615.7205
• DOI: 10.1016/j.pupt.2014.04.003
• Languages: English
• ISSNs: 1094-5539

Abstract

Abstract: Background: Asthma guidelines recommend prescription of inhaled corticosteroids at a reduced dosage in children compared to older patients in order to minimize the systemic exposure and risk of unwanted side effects. In children, pressurized metered dose inhalers (pMDI) are recommended in combination with a valved holding chamber (VHC) to overcome the problem of coordinating inhalation with actuation. However, the influence of age and body size on the systemic exposure of drugs to be administered via a pMDI with VHC is still not fully elucidated. Therefore, we aimed to compare the systemic exposure to the active ingredients of a fixed combination of beclometasone-dipropionate/formoterol-fumarate administered via pMDI with VHC in children, adolescents and adults. Methods: The pharmacokinetics of formoterol and beclometasone-17-monopropionate (active metabolite of beclometasone-dipropionate) was evaluated over 8 h from three studies, each performed in a different age and body size group. Children (7–11 years, n = 20), adolescents (12–17 years, n = 29) and adults (≥18 years, n = 24) received a single dose of beclometasone/formoterol (children: 200 μg/24 μg, adolescents and adults: 400 μg/24 μg) via pMDI with AeroChamber Plus™. Results: The systemic exposure in children in comparison to adolescents was equivalent for formoterol while it was halved for beclometasone-17-monopropionate in accordance with the halved dose of beclometasone administered in children (90% CIs within 0.8–1.25 for formoterol and 0.4–0.625 for beclometasone-17-monopropionate). The systemic exposure to beclometasone-17-monopropionate and formoterol was equivalent between adolescents and adults. Conclusions: The systemic exposure to the active ingredients of a fixed dose combination of beclometasone/formoterol administered via pMDI with AeroChamber Plus™ correlates with the nominal dose independently of patient age and body size. Thus, dose reduction in relation to age when using a pMDI with VHC may be unnecessary for reducing the systemic exposure in children.